-

11:14:51 AM

IMAB Stock News

IMAB - I-Mab

01/18/22 8:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2

RHEA-AI

neutral

01/14/22 8:00 AM

Nasdaq : IMAB

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical

RHEA-AI

neutral

01/12/22 8:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in its China phase

RHEA-AI

very positive

01/06/22 8:00 AM

Nasdaq : IMAB

I-Mab Announces Senior Management Team Share Purchase Plan

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, including

RHEA-AI

neutral

12/31/21 8:00 AM

Nasdaq : IMAB

I-Mab Announces Upcoming Participation at January Conferences

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in January

RHEA-AI

neutral

12/27/21 8:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) of China's National

RHEA-AI

neutral

12/20/21 8:00 AM

Nasdaq : IMAB

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization- Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company's R&D organization, focusing on global pipeline

RHEA-AI

very positive

12/15/21 8:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China's

RHEA-AI

neutral

12/14/21 6:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today reported interim data from an ongoing clinical trial (NCT03934814)

RHEA-AI

neutral

12/09/21 8:00 AM

Nasdaq : IMAB

conferencesclinical trial

I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8:00 a.m. EST on

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IMAB Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.i-mabbiopharma.com/en
Security nameI-Mab - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

IMAB Description:

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.